S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:LPCN

Lipocine - LPCN Stock Forecast, Price & News

$0.53
+0.01 (+1.91%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.49
$0.56
50-Day Range
$0.39
$0.58
52-Week Range
$0.36
$1.89
Volume
118,330 shs
Average Volume
119,180 shs
Market Capitalization
$47.32 million
P/E Ratio
13.37
Dividend Yield
N/A
Price Target
$4.00

Lipocine MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
648.2% Upside
$4.00 Price Target
Short Interest
Bearish
1.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Lipocine in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$10,217 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.13) to ($0.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

899th out of 1,055 stocks

Pharmaceutical Preparations Industry

446th out of 519 stocks


LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Lipocine to Present at Biotech Showcase
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
LPCN: TLANDO Launched
Lipocine: Q2 Earnings Snapshot
Recap: Lipocine Q2 Earnings - Benzinga
Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings
11/09/2022
Today
1/28/2023
Next Earnings (Estimated)
3/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
Employees
13
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+648.2%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-630,000.00
Pretax Margin
24.69%

Debt

Sales & Book Value

Annual Sales
$16.14 million
Cash Flow
$0.05 per share
Book Value
$0.52 per share

Miscellaneous

Free Float
83,908,000
Market Cap
$47.32 million
Optionable
Optionable
Beta
0.60

Social Links


Key Executives

  • Mahesh V. PatelMahesh V. Patel
    President, Chief Executive & Financial Officer
  • George G Nomikos
    Chief Medical Officer
  • Anthony DelConte
    Chief Medical Director
  • Nachiappan Chidambaram
    Vice President-Product Development
  • Krista Fogarty
    Chief Accounting Officer













LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?

0 analysts have issued 12 month price objectives for Lipocine's shares. Their LPCN share price forecasts range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 648.2% from the stock's current price.
View analysts price targets for LPCN
or view top-rated stocks among Wall Street analysts.

How have LPCN shares performed in 2023?

Lipocine's stock was trading at $0.3978 at the beginning of 2023. Since then, LPCN stock has increased by 34.4% and is now trading at $0.5346.
View the best growth stocks for 2023 here
.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our LPCN earnings forecast
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) announced its earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03).

What other stocks do shareholders of Lipocine own?
What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.53.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $47.32 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 1/28/2023 by MarketBeat.com Staff